Table 1 Baseline (at the initiation of TDF treatment) characteristics of the 103 patients

Age, years*

> 60 years old, n (%)

56.7 ± 13

44 (43%)

Male patients, n (%)

58 (56%)

HBeAg– positive, n (%)

8 (7.8%)

Baseline liver stiffness (kPa)*

8.7 ± 6.2

Advanced fibrosis / cirrhosis n (%)

Cirrhosis n (%)

25 (24%)

14 (14%)

Treatment duration with TDF**, months

90 (36–154)

ALT (IU/L)**

36.9 (11-2130)

HBV DNA (log₁₀ IU/L)**

4.8 (2.3–8.8)

Platelet x 10⁹ /L**

200 (57–337)

BMI (Kg/m²)*

≥ 25Kg/m², n (%)

≥ 30 Kg/m², n (%)

25 ± 4

46 (45%)

10 (10%)

Diabetes Mellitus, n (%)

10 (10%)

Hypertension, n (%)

29 (28%)

Dyslipidemia, n (%)

11 (11%)

Metabolic syndrome, n (%)

47 (46%)

Active smokers, n (%)

21 (20%)